Processing

Please wait...

Settings

Settings

1. WO2020033413 - MODULATORS OF RAS GTPASE

Publication Number WO/2020/033413
Publication Date 13.02.2020
International Application No. PCT/US2019/045315
International Filing Date 06.08.2019
IPC
C07D 271/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
C07D 403/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 413/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
C07D 271/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
Applicants
  • TOSK, INC. [US/US]; 2672 Bayshore Parkway, Suite 507 Mountain View, California 94043, US
Inventors
  • LENNEK, Annie L.; US
  • YANOFSKY, Stephen D.; US
  • FRENZEL, Brian D.; US
  • UNGASHE, Solomon B.; US
  • GARLAND, William A.; US
  • LIAW, Philip; US
Agents
  • FIELD, Bret E.; US
Priority Data
62/715,50507.08.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODULATORS OF RAS GTPASE
(FR) MODULATEURS DE RAS GTPASE
Abstract
(EN)
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
(FR)
La présente invention concerne des composés de modulation des RAS et leurs procédés d'utilisation. Les composés trouvent une utilisation dans la modulation de l'activité d'un RAS cible dans un échantillon. Le RAS cible peut être un RAS mutant qui est impliqué dans une maladie d'intérêt. Dans certains cas, les composés de l'invention peuvent inhiber la croissance de cellules cancéreuses dont la progression est entraînée par kRAS ou un kRAS muté. L'invention concerne également des procédés de traitement d'un sujet pour une maladie entraînée par RAS comprenant l'administration d'une quantité thérapeutiquement efficace du composé de l'invention. Des compositions pharmaceutiques et des kits contenant lesdits composés de l'invention sont en outre décrits.
Latest bibliographic data on file with the International Bureau